JMJD6 and ovarian carcinoma: In addition, considering the potential value of JMJD6 in cancer therapy, an inhibitor SKLB325 has been designed based on the crystal structure of the JmjC domain of JMJD6, which has shown significant anti-tumor effects in ovarian cancer [31].